We report design, synthesis, and mechanistic studies of a new mitomycin tetramer 9 along with a new mitomycin dimer 10. Mitomycin 9 is a tetramer connected by the disulfide linker 11, and easily undergoes disulfide cleavage to provide two dimeric structures 9r that each contains a single thiol probe for activations. So, tetramer 9 as a precursor of 9r was specifically targeted to undergo double activations with a single probe. A tetramer 9 was synthesized using 1 and key intermediate 11, and a dimer 10 was synthesized from 1 and diamine 12. Activation studies revealed that 9 underwent effective double activations with a single probe by nucleophiles while the reference 10 did not. Evaluations of DNA ISC formations showed that 9 generated substantial levels of DNA ISC by nucleophilic activation while the references 10 and 2 did not. The effectiveness of 9 in activation and formation of DNA ISC per probe was verified by comparing with dimers 5-8 of double activations with two probes. These findings highlighted the role of a single thiol in 9r and demonstrated the intended double activations with a single probe, which marks the first case in mitomycin studies.

01 Sep 2012·Archives of Pharmacal ResearchQ3 · MEDICINE

Studies on activation mechanism of a mitomycin dimer, 7-N,7′-N′-(1″,2″-dithiepanyl-3″,7″-dimethylenyl)bismitomycin C

Q3 · MEDICINE

Article

Author: Hyoung Rae Kim ; Jae Jin Kim ; Sang Hyup Lee

We report the studies on nucleophilic activation and DNA alkylation of a cyclic disulfide mitomycin dimer, 7-N,7'-N'-(1″,2″-dithiepanyl-3″,7″-dimethylenyl)bismitomycin C (6) along with a diol mitomycin dimer, 7-N,7'-N'-(2″,6″-dihydroxy-1″,7″-heptanediyl)bismitomycin C (7). We wished to see if disulfide mitomycin 6 undergoes efficient nucleophilic activation and corresponding formation of DNA interstrand cross-link (DNA ISC) products compared to diol mitomycin 7. Mitomycin 6 is a dimer connected by a seven-membered cyclic disulfide (a 1,2-dithiepane) linker, and mitomycin 7 is also a dimer containing 2,6-dihydroxyheptane linker that was employed as a reference one to identify the effect of disulfide unit in 6. Through kinetic studies using solvolysis reaction, we found that 6 underwent much faster nucleophilic activation by Et3P compared to 7, and that the enhanced activation rates were induced by the disulfide unit in 6. These findings led us to propose a nucleophilic activation mechanism for 6. We further demonstrated that 6 produced much higher levels of DNA ISC (86%) by the action of Et3P compared with 7 (5%) and 1 (4%). Therefore, we have concluded that 6 was highly efficient for nucleophilic activation and DNA ISC formation due to the key role of cyclic disulfide unit in 6.

01 Jul 2011·Bioorganic & Medicinal ChemistryQ3 · MEDICINE

Synthesis and mechanistic studies of a mitomycin dimer containing an eight-membered cyclic disulfide

Q3 · MEDICINE

Article

Author: Sang Hyup Lee ; Jae Jin Kim ; Eun Sook Kim ; Choon Sik Jeong ; Aree Moon ; Hyun Jung Park ; Hyoung Rae Kim ; Eun Kyung Lee

Dimeric DNA alkylating agents have drawn significant interest because these compounds are expected to provide at least two reactive sites and as a result, generate enhanced levels of DNA interstrand cross-link (DNA ISC) adducts compared to their monomeric agents. We report the synthesis and mechanistic studies of a novel mitomycin dimer, 7-N,7'-N'-(1″,2″-dithiocanyl-3″,8″-dimethylenyl)bismitomycin C (8) connected by an eight-membered cyclic disulfide. Mitomycins require prior activation (i.e., transformation to a good electrophile) for DNA adduction and therefore, 8 was aimed to undergo facile nucleophilic activation and produce enhanced levels of DNA ISC. At the core of this function lies a cyclic disulfide in 8. It was expected that disulfide cleavage by an appropriate nucleophile would successively produce two thiols that may trigger activation of two mitomycin rings in a dimer through intramolecular cyclization to quinine rings. Compound 8 was synthesized from mitomycin A (1) and the key intermediate, cyclic disulfide (11), along with the reference diol mitomycin 7-N,7'-N'-(2″,7″-dihydroxy-1″,8″-octanediyl)bismitomycin C (23) which does not contain the disulfide unit. We found that 8 underwent significantly enhanced nucleophilic activation in the presence of Et(3)P compared with 23, and that the disulfide unit in 8 played a key role for the nucleophilic activation. Based on these findings, we proposed a mechanism for nucleophilic activation of 8. We further demonstrated that 8 generated much higher levels of DNA ISC (94%) compared with 23 (4%) and 2 (3%) in the presence of Et(3)P (and L-DTT) leading to the conclusion that 8 is more efficient for DNA ISC processes than 23 and 2 due to the role of disulfide unit.

100 Deals associated with BMS-181174

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Gastrointestinal Neoplasms	Phase 2	United States	Bristol Myers Squibb Co.	-
Gastrointestinal Neoplasms	Phase 2	Europe	-	-
Lung Cancer	Phase 2	United States	Bristol Myers Squibb Co.	-
Lung Cancer	Phase 2	Europe	-	-
Ovarian Cancer	Phase 2	United States	Bristol Myers Squibb Co.	-
Ovarian Cancer	Phase 2	Europe	-	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

BMS-181174

Overview

Basic Info

Structure/Sequence

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation